By Will Feuer

 

Abbott Laboratories said Wednesday that it has received clearance from the U.S. Food and Drug Administration for its new heart mapping platform.

Abbott's EnSite X EP System with EnSite Omnipolar Technology creates detailed three-dimensional maps of the heart to help physicians better treat abnormal heart rhythms, or cardiac arrhythmias, the company said.

"These models provide a way to precisely identify areas that are causing problems, so physicians can better treat those abnormal heart rhythms, and preserve healthy tissue," said Mike Pederson, senior vice president of electrophysiology at Abbott.

 

Write to Will Feuer at Will.Feuer@wsj.com

 

(END) Dow Jones Newswires

January 12, 2022 09:26 ET (14:26 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.
Abbott Laboratories (NYSE:ABT)
Graphique Historique de l'Action
De Avr 2022 à Mai 2022 Plus de graphiques de la Bourse Abbott Laboratories
Abbott Laboratories (NYSE:ABT)
Graphique Historique de l'Action
De Mai 2021 à Mai 2022 Plus de graphiques de la Bourse Abbott Laboratories